C3 and age-related macular degeneration: In addition, phase 3 clinical data have confirmed the translational relevance of this pathway: the OAKS and DERBY trials showed that complement C3 inhibition with pegcetacoplan significantly slowed the progression of geographic atrophy secondary to AMD over 24 months (33).